AN
ANWA.F Immuron Limited
- Market cap
- EUR 6.13M
- P/E
- -
- P/B
- 0.88x
- ROE
- -33.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ANWA.F undervalued?
Graham numberThe Graham number of Immuron Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immuron Limited fundamental analysis
No fundamental analysis for Immuron Limited yet.
Immuron Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as …
Full company profileImmuron Limited financial statements
Immuron Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.40M | 1.84M | 2.39M | 2.52M | 765K | 1.80M | 4.90M | 7.29M | 7.71M |
| Gross Profit | 516K | 973K | 1.72M | 1.83M | 524K | 1.31M | 3.34M | 4.77M | 4.98M |
| Operating Income | -6.41M | -3.09M | -4.62M | -2.89M | -3.12M | -3.41M | -5.22M | -5.36M | -3.53M |
| EBITDA | -6.77M | -2.99M | -4.63M | -2.86M | -2.81M | -3.73M | -6.88M | -5.16M | -3.62M |
| Net Income | -6.80M | -3.01M | -4.63M | -2.93M | -2.85M | -3.79M | -6.94M | -5.22M | -3.68M |
| EPS | -0.05 | -0.02 | -0.03 | -0.02 | -0.01 | -0.02 | -0.03 | -0.02 | -0.01 |
| Balance Sheet | |||||||||
| Total Assets | 8.29M | 9.24M | 8.56M | 6.20M | 24.9M | 22.0M | 15.5M | 10.1M | 13.2M |
| Total Liabilities | 1.71M | 803K | 1.21M | 558K | 1.68M | 2.37M | 2.84M | 2.06M | 1.99M |
| Shareholders' Equity | 6.57M | 8.44M | 7.35M | 5.64M | 23.2M | 19.6M | 12.7M | 8.07M | 11.2M |
| Cash & Short-term Investments | 3.99M | 4.73M | 5.12M | 3.25M | 22.1M | 17.2M | 11.7M | 2.83M | 9.02M |
| Cash Flow | |||||||||
| Operating Cash Flow | -7.03M | -3.50M | -1.80M | -3.15M | - | - | - | - | - |
| Capital Expenditure | 5.70K | 6.59K | 2.05K | 864.00 | 10.0K | 7.74K | 195.00 | 0.00 | 4.75K |
| Free Cash Flow | -7.04M | -3.53M | -1.80M | -3.15M | -3.16M | -2.60M | -5.88M | -6.14M | -3.26M |
| Ratios | |||||||||
| ROE | -103.5% | -35.7% | -63.0% | -51.9% | -12.3% | -19.3% | -54.6% | -64.6% | -33.0% |
| ROA | -82.1% | -32.6% | -54.1% | -47.2% | -11.5% | -17.2% | -44.6% | -51.5% | -28.0% |
| Net Profit Margin | -487.3% | -163.4% | -194.0% | -116.2% | -373.0% | -209.8% | -141.5% | -71.6% | -47.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Immuron Limited dividends
Immuron Limited has not paid dividends in the last 9 fiscal years.
Who owns Immuron Limited
- Insiders 0.00%
- Institutions 1.20%
- Public & others 98.80%
- Shares outstanding 8.07M
- Free float 6.87M
Immuron Limited company profile
- Company name
- Immuron Limited
- Ticker
- ANWA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- June
- Address
- 62 Lygon Street, Carlton, VIC, Australia, 3053
- Phone
- 61 3 8892 4854
- Website
- immuron.com.au
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Immuron Limited management
6- Mr. Steven George Lydeamore CPA, M.B.A.Chief Executive Officer · born 1968
- Dr. Jerry Kanellos Ph.D.Chief Scientific Officer · born 1961
- Mr. Flavio PalumboChief Commercial Officer · born 1974
- Mr. Aaron LauritaChief Financial Officer
- Mr. David LyonHead of Marketing
- Ms. Olga SmejkalovaCompany Secretary